Diabetes mellitus
Drug research and approvals for diabetes mellitus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 1,967 studies of diabetes mellitus are recruiting on ClinicalTrials.gov, Health Canada has authorized 41 drug trials for it since 2013, FDA has 1 approved and 6 open orphan designations naming it, and the EU has 98 authorised medicines for it.
- Recruiting worldwide: 1,967
- Trials authorized in Canada: 41
- FDA orphan approvals: 1
- EU medicines: 98
Recruiting Now
Newest start dates first, of 1,967 recruiting on ClinicalTrials.gov ↗- The Effects of Increased Water Intake on Muscle Function, Physical Performance, and Endocrine Regulation in…NCT07892742 · Not applicable · Polytechnic University of Santarém · starts Jan 1, 2027
- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine,…NCT07083557 · Not reported · Bettina Mittendorfer · starts Jan 1, 2027
- Thrive With Type 1 Diabetes 2026NCT07522866 · Not applicable · Emory University · starts Dec 1, 2026
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced…NCT07748208 · Phase 2 · Hoffmann-La Roche · starts Nov 30, 2026
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerNCT07808151 · Phase 2 · Solstice Oncology, Inc. · starts Nov 30, 2026
- Measuring Plantar Pressures in Diabetic Patients With Lateral Forefoot AmputationNCT07865208 · Not reported · Nanyang Technological University · starts Nov 27, 2026
- C-Carbs: A CGM-guided Approach to Teaching Carb AwarenessNCT07807280 · Not applicable · University of California, Los Angeles · starts Nov 16, 2026
- PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and…NCT07670650 · Phase 3 · University of Florida · starts Nov 10, 2026
- Whole-Body Vibration Training in Women With Obesity With and Without Type 2 DiabetesNCT07924436 · Not applicable · Pamukkale University · starts Nov 9, 2026
- Fulvic Acid Supplementation and Metabolic SyndromeNCT07927283 · Not applicable · Arizona State University · starts Nov 6, 2026
Trials Authorized in Canada
The 10 newest of 41; search them all in Canada trials| Jun 24, 2026 | A phase 3, randomized, double-blind extension trial to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants…MARIDEBART CAFRAGLUTIDE (AMG 133) | Amgen | Ongoing |
| May 12, 2026 | A randomized, double-blind, parallel-group phase III study to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults…ELECOGLIPRON (AZD5004) | AstraZeneca Pharmaceuticals LP | Ongoing |
| Mar 17, 2025 | A phase 3 randomized, double-blind, placebo controlled study to evaluate the efficacy, safety, and tolerability of maridebart cafraglutide in adult…MARIDEBART CAFRAGLUTIDE (AMG 133) | Amgen | Ongoing |
| Sep 6, 2024 | A phase IIb randomised, double-blind, placebo-controlled and open-label active comparator study to evaluate the efficacy, safety and tolerability of azd5004 in…AZD5004 | AstraZeneca Pharmaceuticals LP | Closed |
| Jan 19, 2023 | A phase 1/2, randomized, double-blind, placebo-controlled, 2-part study of the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of single…ALN-KHK (ALN-1613400) | Alnylam Pharmaceuticals | Closed |
| Dec 23, 2022 | A phase 1/2 study to evaluate the safety, tolerability, and efficacy of vx-264 in subjects with type 1 diabetes mellitusVX-264 | Vertex Pharmaceuticals | Ongoing |
| Oct 14, 2022 | An open-label, first-in-human safety evaluating the safety, tolerability, and efficacy of vctx211 combination product in subjects with type 1 diabetes mellitus…VCTX211 / TACROLIMUS / THYMOGLOBULIN | CRISPR THERAPEUTICS AG | Closed |
| Aug 8, 2022 | A phase 1/2 randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and…ICOVAMENIB (BMF-219) | BIOMEA FUSION, INC. | Closed |
| Nov 22, 2019 | A phase II, randomized, parallel group, dose-finding study of subcutaneously administered bi 456906 for 16 weeks, compared with placebo and open-label…BI 456906 | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Closed |
| Jan 14, 2019 | A phase 3b, randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with…DASIGLUCAGON | Zealand Pharma | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first| Feb 17, 2012 | Korlymfor the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2… | Corcept Therapeutics, Inc. | Approved |
| Feb 5, 2026 | recombinant human insulintreatment of neonatal diabetes mellitus (monogenic forms of diabetes mellitus that present in infancy) | Hellene Solomon Wan, MD - Induvidual sponsor. | Designated |
| Jan 12, 2017 | anti-interleukin 21 (NNC0114-0006) in combination with…Treatment of Type I Diabetes Mellitus with residual beta cell function. | Novo Nordisk, Inc. | Designated |
| Mar 3, 2015 | alpha1-proteinase inhibitor (human)Treatment of Type 1 diabetes mellitus patients with residual beta-cell function. | Grifols Therapeutics, Inc. | Designated |
| Dec 20, 2013 | CD40/CD80/CD86 modified autologous dendritic cell therapyTreatment Type 1 diabetes mellitus patients with residual beta cell function | DiaVacs, Inc. | Designated |
| May 30, 2013 | abataceptTreatment of type 1 diabetes mellitus patients with residual beta cell function | Orban Biotech LLC | Designated |
| Jul 28, 2011 | alpha-1 proteinase inhibitor (human)Treatment of patients with recent onset (<15 years)with Type 1A diabetes mellitus with residual beta-cell function | Kamada, Ltd. | Designated |
Medicines Authorised in the EU
Newest first; 15 of 98| Jul 15, 2026 | Liraglutide STADAliraglutide | STADA Arzneimittel AG | EMA ↗ |
| May 6, 2026 | Bysumloginsulin lispro · biosimilar | Sandoz GmbH | EMA ↗ |
| Apr 27, 2026 | Dazpardainsulin aspart · biosimilar | Sandoz GmbH | EMA ↗ |
| Jan 9, 2026 | Ondibtainsulin glargine · biosimilar | Sandoz GmbH | EMA ↗ |
| Jan 8, 2026 | Teizeildteplizumab | Sanofi Winthrop Industrie | EMA ↗ |
| Nov 24, 2025 | Kyinsuinsulin icodec;semaglutide | Novo Nordisk A/S | EMA ↗ |
| Jul 24, 2024 | Zegaloguedasiglucagon | Zealand Pharma A/S | EMA ↗ |
| May 17, 2024 | Awiqliinsulin icodec | Novo Nordisk A/S | EMA ↗ |
| Mar 31, 2023 | Sitagliptin / Metformin hydrochloride Sunsitagliptin;metformin hydrochloride · generic | Sun Pharmaceutical Industries Europe B.V. | EMA ↗ |
| Mar 24, 2023 | Dapagliflozin Viatrisdapagliflozin · generic | Viatris Limited | EMA ↗ |
| Sep 15, 2022 | Mounjarotirzepatide | Eli Lilly Nederland B.V. | EMA ↗ |
| Apr 25, 2022 | Sitagliptin Accordsitagliptin · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Mar 24, 2022 | Vildagliptin / Metformin hydrochloride Accordvildagliptin;metformin hydrochloride · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Feb 16, 2022 | Sitagliptin / Metformin hydrochloride Mylansitagliptin hydrochloride monohydrate;metformin hydrochloride · generic | Mylan Pharmaceuticals Limited | EMA ↗ |
| Dec 9, 2021 | Sitagliptin SUNsitagliptin fumarate · generic | Sun Pharmaceutical Industries Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA